Ginkgo Bioworks Holdings, Inc. cash flow to debt ratio of -38.89% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Ginkgo Bioworks Holdings, Inc.'s free cash flow has increased -53.23% from $-382.13M last year to $-178.72M, signaling increasing performance

Ginkgo Bioworks Holdings, Inc.'s debt to equity ratio is 0.93, which means that the company's assets are unhealthy financed, signaling financial risk. READ MORE: A ratio over 0.60 means the company finances its assets with debt, signaling financial risk. If ratio is negative, the company spent its own equity and risks bankruptcy

Ginkgo Bioworks Holdings, Inc.'s debt has increased relative to shareholder equity from 0.65 last year to 0.93 today, signaling weakened financials

Ginkgo Bioworks Holdings, Inc. has negative EBITDA, making leverage ratio unreliable

Ginkgo Bioworks Holdings, Inc. earns at least as much interest as it pays. Interest obligations are fully covered.

Ginkgo Bioworks Holdings, Inc.'s profit margin has increased (-10.60%) in the last year from -240.94% to -215.41%, signaling increasing performance

Ginkgo Bioworks Holdings, Inc.'s short-term assets of $471.84M exceed its short-term liabilities of $95.97M

Ginkgo Bioworks Holdings, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Ginkgo Bioworks Holdings, Inc.'s return on equity of -57.31%, is lower than 15.00%, indicating bad performance

Ginkgo Bioworks Holdings, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Ginkgo Bioworks Holdings, Inc. had positive net income in only 0.00 out of 5 years, indicating unstable earnings

Ginkgo Bioworks Holdings, Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

Ginkgo Bioworks Holdings, Inc. has negative free cash flow, indicating cash burn

Ginkgo Bioworks Holdings, Inc.'s yearly earnings has increased -42.83% since last year from $-547.03M to $-312.76M, signaling increasing performance

Ginkgo Bioworks Holdings, Inc.'s yearly revenue has decreased -25.06% since last year from $227.04M to $170.16M, signaling decreasing performance

ROIC -31.12% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Ginkgo Bioworks Holdings, Inc.'s 3-year revenue CAGR of -29.11% is negative, indicating declining revenue over the past 3 years

Ginkgo Bioworks Holdings, Inc. had revenue growth in only 2.00 out of 5 years, indicating inconsistent revenue performance

Ginkgo Bioworks Holdings, Inc. had positive ROE in only 0.00 out of 5 years, indicating inconsistent returns on equity

Ginkgo Bioworks Holdings, Inc. has insufficient data to evaluate this check.

Ginkgo Bioworks Holdings, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Ginkgo Bioworks Holdings, Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

Ginkgo Bioworks Holdings, Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Ginkgo Bioworks Holdings, Inc. is overvalued relative to its fair value price of -204.14 based on Earnings Fair Value model

Ginkgo Bioworks Holdings, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Ginkgo Bioworks Holdings, Inc. has a price-to-book ratio of 1.22x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

Ginkgo Bioworks Holdings, Inc. has a price-to-sales ratio of 3.81x, which is below the 8.00x threshold, indicating reasonable valuation relative to its revenue